GUILLERMO
LÓPEZ VIVANCO
Chercheur jusqu' 2022
Hospital Universitario Puerta de Hierro
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario Puerta de Hierro (16)
2023
-
Immunogenicity of COVID-19 vaccines in lung cancer patients
Lung Cancer, Vol. 184
-
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513
2022
-
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
Annals of Oncology, Vol. 33, Núm. 1, pp. 67-79
-
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
Journal of Clinical Oncology, Vol. 71
-
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study
Translational Lung Cancer Research, Vol. 11, Núm. 1, pp. 53-63
-
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
Journal for immunotherapy of cancer, Vol. 10, Núm. 9
2021
-
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 8
-
Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy
Clinical Cancer Research, Vol. 27, Núm. 21, pp. 5878-5890
2020
-
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422
2019
-
Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer
Journal of Thoracic Oncology, Vol. 14, Núm. 2, pp. 304-310
2017
-
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
Journal of the National Cancer Institute, Vol. 109, Núm. 9
2014
-
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies
Annals of Oncology, Vol. 25, Núm. 11, pp. 2147-2155
2012
2010
-
Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients
Lung Cancer, Vol. 68, Núm. 3, pp. 491-497
2009
-
Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
PLoS ONE, Vol. 4, Núm. 5
-
Screening for epidermal growth factor receptor mutations in lung cancer
New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967